Rijpkema, S; Hockley, J; Logan, A; Rigsby, P; Atkinson, E; Jin, C; Goldblatt, D; ... anti-Vi IgG working group; + view all Rijpkema, S; Hockley, J; Logan, A; Rigsby, P; Atkinson, E; Jin, C; Goldblatt, D; Liang, H; Bachtiar, NS; Yang, JS; Goel, A; Ramasamy, V; Pasetti, MF; Pollard, AJ; anti-Vi IgG working group; - view fewer (2018) Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. Biologicals , 56 pp. 29-38. 10.1016/j.biologicals.2018.09.001.

Preview

Text Goldblatt VoR 1-s2.0-S1045105618302835-main.pdf - Published Version Download (1MB) | Preview

Abstract

Vi capsular polysaccharide (Vi) conjugate vaccines, which can prevent typhoid in infants and young children, are being developed. Comparative immunogenicity studies are facilitated by an International Standard (IS) for human anti-Vi IgG. 16/138, a pool of sera from volunteers which received either Vi conjugate vaccine or plain Vi vaccine, was assessed as an IS alongside U.S. reference reagent Vi-IgGR1, 2011. Samples were tested in a commercial ELISA (n = 7), a standardised ELISA based on biotinylated Vi (n = 7) and in-house ELISAs (n = 7). Valid estimates were obtained for the potency of all samples in the commercial ELISA, and the commutability of 16/138 and Vi-IgGR1, 2011 was evident for the commercial ELISA and in-house ELISAs based on a coating of Vi and protein. The WHO Expert Committee on Biological Standardization established 16/138 as the first IS for anti-Vi IgG with 100 IU per ampoule and assigned 163 IU per vial of Vi-IgGR1, 2011.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item